<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146273</url>
  </required_header>
  <id_info>
    <org_study_id>SSPA-17-1</org_study_id>
    <nct_id>NCT03146273</nct_id>
  </id_info>
  <brief_title>Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)</brief_title>
  <official_title>A Pharmacokinetic Crossover Comparison Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galilee CBR</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galilee CBR</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to evaluate difference in the AUC of the absorption of&#xD;
      Multivitamin and minerals defined in the protocol&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is designed to evaluate difference in the AUC of the absorption of&#xD;
      Multivitamin and minerals:&#xD;
&#xD;
        1. Tablet/capsule administration - up to 20 healthy volunteers will be recruited to the&#xD;
           study. The tablet/capsule will be administered as a single dose after 12 hours of&#xD;
           fasting. The participants will be monitored during 6 hours for the level of minerals and&#xD;
           Multivitamin minerals in the blood, adverse events and vital signs.&#xD;
&#xD;
        2. Gel administration - the gel will be administrated to the same group of patients in the&#xD;
           single dose after 12 hours of fasting. The participants will be monitored during 6 hours&#xD;
           for the level of minerals and Multivitamin minerals in the blood, adverse events and&#xD;
           vital signs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 9, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean fractional absorption</measure>
    <time_frame>6 hours</time_frame>
    <description>A comparison of mean fractional absorption of the two Multivitamin mineral formulations (gel vs. tablet/capsule).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absorption rate</measure>
    <time_frame>6 hours</time_frame>
    <description>A comparison of absorption rate across the two Multivitamin mineral formulations (gel vs. tablet/capsule).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vitamin Deficiency</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamins</intervention_name>
    <description>After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium&#xD;
After the washout period, the same procedure will be done for the additional formulation of the multivitamins.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female and aged 18-65 years&#xD;
&#xD;
          -  BMI - 19-24&#xD;
&#xD;
          -  Subject is not pregnant and is not nursing&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of multivitamin or mineral complexes (washout of 4 days before Visit 2 is&#xD;
             permitted)&#xD;
&#xD;
          -  Participants with known vitamins or mineral deficiencies&#xD;
&#xD;
          -  Diabetes Type II&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Subjects who have undergone surgery within the last 3 months.&#xD;
&#xD;
          -  Subjects with a clinically significant (during last 3 months) infectious,&#xD;
             immune-mediated or active malignant disease.&#xD;
&#xD;
          -  Subjects who are receiving an elemental diet or parenteral nutrition.&#xD;
&#xD;
          -  Subjects who are treated with insulin.&#xD;
&#xD;
          -  Women with childbearing potential unless surgically sterile or using adequate&#xD;
             contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus&#xD;
             spermicide); pregnant or breastfeeding mothers.&#xD;
&#xD;
          -  Subjects who will be unavailable for the duration of the trial, who are unlikely to be&#xD;
             compliant with the protocol, or who are felt to be unsuitable by the Investigator for&#xD;
             any other reason.&#xD;
&#xD;
          -  Known sensitivity to any ingredients in the study product&#xD;
&#xD;
          -  History of addiction or drug abuse&#xD;
&#xD;
          -  Alcoholic regular use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 6, 2017</study_first_submitted>
  <study_first_submitted_qc>May 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 6, 2017</last_update_submitted>
  <last_update_submitted_qc>May 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avitaminosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study results will be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

